ArticleJournal of ovarian research2025
Oleic acid activates TGFβ-Smad3 signaling to promote ovarian cancer progression.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Subtype-specific mechanisms of lipid metabolism in gynecological malignancies and novel targeted intervention strategies (Review).Oncology letters · 2026Review
- Mechanisms of fatty acid metabolism in tumor metastasis and targeted therapeutic strategies.Discover oncology · 2026Review
- Albumin Nanoparticle-Based Delivery of Oxaliplatin-Oleic Acid Prodrug for Enhanced Breast Cancer Therapy.AAPS PharmSciTech · 2026Article
- Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigms.Oncology reviews · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundOvarian cancer represents the most aggressive and lethal gynecological cancer, frequently demonstrating a distinct propensity for abdominal metastasis. Malignant ascites caused by abdominal metastasis provide a tumor microenvironment (TME) in ovarian cancer. Notably, oleic acid is abundant in ovarian cancer ascites, though its functional significance in TME modulation and tumor metastatic regulation remains poorly characterized. Stearoyl-CoA desaturase 1 (SCD1) is the key enzyme in the synthesis of oleic acid. Our study systematically explores the pathological role of oleic acid and evaluates the therapeutic effects of SCD1 inhibitor in ovarian cancer progression.
resultsOleic acid treatment significantly enhanced proliferation of ovarian cancer cells and patient-derived organoids. Remarkably, oleic acid also increased membrane fluidity and promoted cell migration. Mechanistically, TGFβ-Smad3 signaling cascade is selectively activated by oleic acid, and inhibited by SCD1 suppression. Importantly, activation of Smad3 caused by oleic acid treatment triggered epithelial-mesenchymal transition of ovarian cancer cells. Clinical relevance was established that SCD1 expression was positively correlated with the activity of Smad3 in ovarian cancer tissues. Finally, in vivo studies showed that SCD1 inhibitor treatment suppressed tumor progression during intraperitoneal dissemination.
conclusionThis study provides novel insights into the supporting role of oleic acid in fueling tumor proliferation and metastasis, mechanistically associated with its specific activation of TGFβ-Smad3 signaling. Therapeutically, pharmacological targeting oleic acid synthesis by SCD1 inhibitor emerges as a promising strategy for precision oncology in ovarian cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.